Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01661842
Other study ID # Beijing302-006
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received August 5, 2012
Last updated May 30, 2013
Start date October 2011
Est. completion date October 2014

Study information

Verified date May 2013
Source Beijing 302 Hospital
Contact Fu-Sheng Wang, professor
Phone 86-10-63879735
Email fswang302@163.com
Is FDA regulated No
Health authority China: Ministry of Health
Study type Interventional

Clinical Trial Summary

Autoimmune hepatitis (AIH) is characterized by chronic inflammation of the liver, interface hepatitis, hypergammaglobulinemia, and the presence of autoantibodies. Disease presentation is varied but typically is based on characteristic aminotransferase elevations, histological abnormalities, elevated levels of serum globulins, and the presence of one or more autoantibodies. Two types of juvenile AIH have been identified according to seropositivity for smooth muscle and /or antinuclear antibody (AIH type 1) or liver kidney microsomal antibody (AIH type 2). Standard therapy in clinic consists of a combination of corticosteroids and azathioprine, which displays the efficacy in 80% of patients. However, 7% of patients deteriorate despite compliance with the standard corticosteroid regiments (treatment failure),13% of patients improve but not to a degree that satisfies remission criteria (incomplete response), 13% of patients develop serious drug-induced complications, and 50%-86% of patients will relapse after drug withdrawal. These serious drawbacks counterbalance the benefits of conventional therapy, and they are compelling reasons to refine current treatment strategies and pursue alternative therapies. UC-MSC has been the application for the treatment of several severe autoimmune diseases, such as immune thrombocytopenia, systemic lupus erythematosus, and therapy-resistant rheumatoid arthritis. In this study, the safety and efficacy of UC-MSC transplantation for AIH patients will be evaluated.


Description:

Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological feature of interface hepatitis. Standard therapy consists of a combination of corticosteroids and azathioprine, which is efficacious in 80% of patients. However, current treatment strategies are complicated by frequent relapse after drug withdrawal, medication intolerance, and refractory disease. Alternative medical therapy may be need for AIH.

The potential for stem cells to differentiate into hepatocytes cells was recently confirmed. In particular, bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has been applicated in the clinic for treat several human disease such as GVHD, cardiac injury and brain injury, and displayed good tolerance and efficiency. Recently, umbilical cord-derived MSCs (UC-MSC) has also been used to treat severe autoimmune diseases, such as immune thrombocytopenia, systemic lupus erythematosus, and therapy-resistant rheumatoid arthritis.

The purpose of this study is to learn whether and how UC-MSC can improve the disease condition in patients with autoimmune hepatitis (AIH). This study will also look at how well UC-MSC is tolerated and its safety in AIH patients

Participants in the study will be randomly assigned to one of two treatment arms:

Arm A: Participants will receive 12 weeks of UC-MSC treatment plus conventional treatment (combination of corticosteroids and azathioprine) Arm B: Participants will receive 12 weeks of placebo plus conventional treatment. (combination of corticosteroids and azathioprine) UC-MSC will be prepared according to standard procedures and is collected in plastic bags containing anticoagulant. UC-MSCs are given via i.v. under sonography monitoring. After cell therapy, patients are followed up at week 12, 24, 36, 48, 72, 96. The evaluation of some clinical parameters such as the level of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-globulin, total bilirubin (TB), prothrombin time (PT), albumin (ALB), prealbumin (PA) and IgG, are detected at these time points. MELD score, Liver histology, treatment side effects, relapse rate and clinical symptoms were also observed simultaneously.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Written informed consent

2. Autoimmune hepatitis (according to the criteria defined by the international autoimmune hepatitis Group ,Hepatology, 2008;48:169-176)

3. Negative pregnancy test (female patients in fertile age)

Exclusion Criteria:

1. Hepatocellular carcinoma or other Malignancies

2. Pregnant or lactating women

3. Viral Hepatitis ( HAV,HBV,HCV, et al )

4. Vital organs failure (Cardiac, Renal or Respiratory, et al)

5. Sepsis

6. Active thrombosis in the portal or hepatic veins

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Other:
conventional plus UC-MSC treatment
Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Conventional plus placebo treatment
Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks

Locations

Country Name City State
China Beijing 302 Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing 302 Hospital

Country where clinical trial is conducted

China, 

References & Publications (7)

Czaja AJ. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci. 2012 Aug;57(8):1996-2010. doi: 10.1007/s10620-012-2151-2. Epub 2012 Apr 3. Review. — View Citation

Czaja AJ. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des. 2011;17(29):3120-40. Review. — View Citation

Gossard AA, Lindor KD. Autoimmune hepatitis: a review. J Gastroenterol. 2012 May;47(5):498-503. doi: 10.1007/s00535-012-0586-z. Epub 2012 Apr 17. Review. — View Citation

Holbro A, Abinun M, Daikeler T. Management of autoimmune diseases after haematopoietic stem cell transplantation. Br J Haematol. 2012 May;157(3):281-90. doi: 10.1111/j.1365-2141.2012.09070.x. Epub 2012 Feb 24. Review. — View Citation

Malekzadeh Z, Haghazali S, Sepanlou SG, Vahedi H, Merat S, Sotoudeh M, Nasseri-Moghaddam S, Malekzadeh R. Clinical features and long term outcome of 102 treated autoimmune hepatitis patients. Hepat Mon. 2012 Feb;12(2):92-9. doi: 10.5812/hepatmon.808. Epub 2012 Feb 29. — View Citation

Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007 Oct;46(4):1138-45. — View Citation

Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 2012 Feb;35(2):213-21. doi: 10.1007/s12272-012-0202-z. Epub 2012 Feb 28. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Liver Histology change baseline and 96 weeks No
Primary Serum alanine aminotransferase (ALT) 0,12, 24, 36, 48, 72, 96 weeks after treatment No
Secondary Serum AST At baseline and at week 12, 24, 36, 48, 72, 96 No
Secondary Serum Tbil At baseline and at week 12, 24, 36, 48, 72, 96 No
Secondary Serum immunoglobulin G (IgG) At baseline and at week 12, 24, 36, 48, 72, 96 No
Secondary Serum ?-globulin At baseline and at week 12, 24, 36, 48, 72, 96 No
Secondary MELD score At base line and at week 12, 24, 36, 48, 72, 96 No
Secondary Number of participants with treatment side effects weight gain, acne, facial rounding, dorsal hump formation, hirsutism, osteopenia and diabetes mellitus, et al At base line and at week 12, 24, 36, 48, 72, 96 No
Secondary Number of participants with improvement of clinical symptoms diffuse arthralgias, fatigue, generalized malaise, jaundice, abdominal pain, nausea, and loss of appetite At base line and at week 12, 24, 36, 48, 72, 96 No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06020976 - Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
Recruiting NCT05476900 - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06250309 - Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients N/A
Terminated NCT04339621 - AIH Risk Stratification With Multiparametric MRI
Not yet recruiting NCT04371718 - Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) Phase 2
Completed NCT02239562 - sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS Phase 1
Recruiting NCT05569759 - A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) Phase 2
Completed NCT02463331 - Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis Phase 4
Not yet recruiting NCT06356506 - A Study on Factors of Biochemical Response in Autoimmune Hepatitis
Terminated NCT04203875 - Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis Phase 1
Recruiting NCT06078098 - Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
Completed NCT00838214 - Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Phase 2/Phase 3
Recruiting NCT05810480 - PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
Recruiting NCT03743272 - Repeatability and Reproducibility of Multiparametric MRI
Completed NCT03979053 - Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Recruiting NCT04933292 - A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome Phase 4
Not yet recruiting NCT06455280 - SIPLIZUMAB in AILD and LT Phase 1
Completed NCT05532345 - Discrimination of DILI and AIH by Artificial Intelligence